Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Evofem Biosciences, Inc. (EVFM)

0.0248   -0.01 (-29.14%) 03-24 15:59
Open: 0.0321 Pre. Close: 0.035
High: 0.04 Low: 0.0192
Volume: 17,174,669 Market Cap: 4(M)

Technical analysis

as of: 2023-03-24 4:25:47 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.03     One year: 0.05
Support: Support1: 0.01    Support2: 0.01
Resistance: Resistance1: 0.03    Resistance2: 0.04
Pivot: 0.02
Moving Average: MA(5): 0.02     MA(20): 0.02
MA(100): 0.05     MA(250): 0.61
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 73     %D(3): 70.2
RSI: RSI(14): 44.5
52-week: High: 5.55  Low: 0.01
Average Vol(K): 3-Month: 3,669 (K)  10-Days: 7,718 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EVFM ] has closed below upper band by 44.5%. Bollinger Bands are 2.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.04 - 0.04 0.04 - 0.04
Low: 0.02 - 0.02 0.02 - 0.02
Close: 0.02 - 0.02 0.02 - 0.03

Company Description

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Headline News

Thu, 23 Mar 2023
CapitalGainsReport: Thursday’s OTC Watchlist (EVFM, EPAZ, NWBO, VDRM) - Yahoo Finance

Tue, 21 Mar 2023
Evofem Biosciences Announces Cost Reduction Measures - PR Newswire

Tue, 14 Mar 2023
EVOFEM BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) -

Tue, 14 Mar 2023
Evofem Biosciences Inc. (OTCMKTS:EVFM) Appoints Interim Chief Financial Officer - Evofem Biosciences (OTC - Benzinga

Thu, 09 Mar 2023
Evofem Biosciences Appoints Interim Chief Financial Officer ... - Benzinga

Mon, 27 Feb 2023
Evofem Biosciences Announces FDA Orange Book Listing of Two ... - PR Newswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  PNK
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 170 (M)
Shares Float 121 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 4.1 (%)
Shares Short 8,680 (K)
Shares Short P.Month 17,820 (K)

Stock Financials

EPS -4.39
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.76
Profit Margin (%) 0
Operating Margin (%) -541.4
Return on Assets (ttm) -124.8
Return on Equity (ttm) 0
Qtrly Rev. Growth 272.1
Gross Profit (p.s.) 0.02
Sales Per Share 0.11
EBITDA (p.s.) -0.64
Qtrly Earnings Growth 0
Operating Cash Flow -85 (M)
Levered Free Cash Flow -36 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.04
Price to Sales 0.2
Price to Cash Flow -0.05

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-01-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.